Cell Engineering was Ginkgo Bioworks Holdings’s largest product and service line in fiscal 2025, bringing in $132.75M of $170.16M (78%).
| Product and Service | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|
| Cell Engineering | $143.67M | $143.53M | $173.97M | $132.75M | |||
| Cell Engineering Revenue | — | — | — | — | |||
| Service | $298.59M | $78.98M | $53.07M | $37.41M | |||
| Foundry Revenue | — | — | — | — | |||
| Product | $35.46M | $28.95M | — | — | |||
| Total | $477.71M | $251.46M | $227.04M | $170.16M |
Ginkgo Bioworks Holdings brought in $170.16M from its two product and service lines in fiscal 2025, the year ended December 31, 2025. That was down 25.1% from $227.04M in fiscal 2024. Cell Engineering was the largest at $132.75M (78.0%), ahead of Service at $37.41M (22.0%).
Compared with fiscal 2024, Cell Engineering fell 23.7% to $132.75M and Service fell 29.5% to $37.41M.
Ginkgo Bioworks Holdings stopped reporting Product as a separate line after fiscal 2023, when it brought in $28.95M.
Cell Engineering was Ginkgo Bioworks Holdings’s largest segment in fiscal 2025, bringing in $132.75M of $170.16M (78%).
| Segment | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|
| Biosecurity | $334.04M | $107.92M | $53.07M | $37.41M | |
| Cell Engineering | $143.67M | $143.53M | $173.97M | $132.75M | |
| Total | $477.71M | $251.46M | $227.04M | $170.16M |
Ginkgo Bioworks Holdings brought in $170.16M from its two segments in fiscal 2025, the year ended December 31, 2025. That was down 25.1% from $227.04M in fiscal 2024. Cell Engineering was the largest at $132.75M (78.0%), ahead of Biosecurity at $37.41M (22.0%).
Compared with fiscal 2024, Cell Engineering fell 23.7% to $132.75M and Biosecurity fell 29.5% to $37.41M. From fiscal 2022 to 2025, combined revenue from these segments fell from $477.71M to $170.16M, a compound annual decline of 29.1%. Cell Engineering's share of the total rose from 30.1% to 78.0%.
Ginkgo Bioworks Holdings (DNA) reports its revenue by product and service and by segment. In fiscal 2025, Cell Engineering was its largest product and service line, bringing in $132.75M (78.0% of the total), followed by Service at $37.41M (22.0%).
Cell Engineering was Ginkgo Bioworks Holdings' largest product and service line in fiscal 2025, bringing in $132.75M, or 78.0% of the $170.16M total across its two product and service lines.
Cell Engineering was Ginkgo Bioworks Holdings' largest segment in fiscal 2025, bringing in $132.75M, or 78.0% of the $170.16M total across its two segments.
Every figure comes from Ginkgo Bioworks Holdings' annual financial filings, as reported. Each line keeps the name Ginkgo Bioworks Holdings gives it, and years follow its fiscal calendar.
Ginkgo Bioworks Holdings' revenue by product and service goes back to fiscal 2019, with figures through fiscal 2025. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.